Sugi Predict

Sugi Predict / Compounds / SCHEMBL2851697

SCHEMBL2851697

SCHEMBL2851697

CN(Cc1cccc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HSD17B2 P37059 6/20 0.58
▸ HSD17B1 P14061 4/20 0.58
▸ AOC3 Q16853 6/20 0.55
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ TPH1 P17752 2/20 0.53
▸ GRIA2 P42262 1/20 0.53
▸ ALPI P09923 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ XIAP P98170 1/20 0.51
▸ SLC7A5 Q01650 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2847856 1.00 HSD17B2 (0.58) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL3439044 1.00 HSD17B2 (0.58) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6183482 0.91 HSD17B2 (0.60) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6184250 0.90 HSD17B2 (0.57) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6184066 0.88 HSD17B2 (0.58) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6184210 0.86 HSD17B2 (0.56) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6182989 0.84 PPARG (0.62) HSD17B2HSD17B1
SCHEMBL6184749 0.84 HSD17B2 (0.56) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6473087 0.84 HSD17B2 (0.54) HSD17B2HSD17B1AOC3MEN1KMT2A
SCHEMBL6184961 0.84 HSD17B2 (0.54) HSD17B2HSD17B1AOC3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807669-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-10-05 — — US disclosed
EP-1575911-B1 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2010-01-13 — — EP disclosed
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-03-05 — — US disclosed
US-7452878-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-11-18 — — US disclosed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF PPARG, PPARA, PPARD HSD17B2 448/4885HSD17B1 321/4885AOC3 2202/4885
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD HSD17B2 448/4885HSD17B1 321/4885AOC3 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.